Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients.
According to Cellectar, iopoffosine I 131 has been granted Rare Pediatric Drug and Orphan Drug Designations for pHGG. Iopofosine I 131 was well tolerated and its toxicity profile was consistent with the company’s previously reported safety data. Importantly, patients on iopofosine I 131 did not experience any cardiovascular, renal, or liver toxicities, and no peripheral neuropathy or significant bleeding. The safety profile was consistent with selective targeting of tumor sites with clinically negligible off-target effect outside the hematologic system. The most frequently reported treatment emergent adverse events were hematologic in nature (thrombocytopenia, neutropenia and anemia) and were predictable and manageable. All patients recovered from cytopenias.
Jarrod Longcor, COO of Cellectar, said, “We are highly encouraged with these initial findings from the CLOVER-2 trial in pediatric patients with high-grade glioma. Iopofosine I 131 observed extended PFS and survival, indicating potential signs of clinical efficacy for the treatment of these deadly cancers. We believe this outcome further validates the clinical potential of iopofosine I 131 to treat aggressive cancers for patients with limited treatment options.”
